Open Access. Powered by Scholars. Published by Universities.®
- Publication
- Publication Type
Articles 1 - 6 of 6
Full-Text Articles in Medicine and Health Sciences
Piglet Immunization With A Spike Subunit Vaccine Enhances Disease By Porcine Epidemic Diarrhea Virus, Jieshi Yu, Chithra Sreenivasan, Tirth Uprety, Rongyuan Gao, Chen Huang, Ella J. Lee, Steven Lawson, Julie Nelson, Jane Christopher-Hennings, Radhey S. Kaushik, Eric Nelson, Diego G. Diel, Ben M. Hause, Feng Li, Dan Wang
Piglet Immunization With A Spike Subunit Vaccine Enhances Disease By Porcine Epidemic Diarrhea Virus, Jieshi Yu, Chithra Sreenivasan, Tirth Uprety, Rongyuan Gao, Chen Huang, Ella J. Lee, Steven Lawson, Julie Nelson, Jane Christopher-Hennings, Radhey S. Kaushik, Eric Nelson, Diego G. Diel, Ben M. Hause, Feng Li, Dan Wang
Maxwell H. Gluck Equine Research Center Faculty Publications
Immunization with an insect cell lysate/baculovirus mixture containing recombinant porcine epidemic diarrhea virus (PEDV) spike protein induced high levels of neutralizing antibodies in both mice and piglets. However, immunization of piglets with this vaccine resulted in enhancement of disease symptoms and virus replication in vaccine recipients exposed to PEDV challenge. Thus, these observations demonstrate a previously unrecognized challenge of PEDV vaccine research, which has important implications for coronavirus vaccine development.
Rhodococcus Equi In The Foal – Improving Diagnostic And Prevention Measures, Fernanda Bicudo Cesar
Rhodococcus Equi In The Foal – Improving Diagnostic And Prevention Measures, Fernanda Bicudo Cesar
Theses and Dissertations--Veterinary Science
Although Rhodococcus equi (R. equi), previously known as Corynebacterium equi, was first isolated from pneumonic foals almost a century ago, it remains the most common cause of subacute or chronic granulomatous bronchopneumonia in foals. While the majority of foals exposed to R. equi develop a protective immune response (regressors), others exhibit a unique susceptibility to infection (progressors). The determinants for either outcome are not completely understood. Therefore, current diagnostic and preventive measures are suboptimal and require betterment. In light of this current need, we hypothesized that immunoglobulin G subisotype T [IgG(T)] against the virulence-associated protein A (VapA) …
Envelope Determinants Of Equine Lentiviral Vaccine Protection, Jodi K. Craigo, Corin Ezzelarab, Sheila J. Cook, Chong Liu, David W. Horohov, Charles J. Issel, Ronald C. Montelaro
Envelope Determinants Of Equine Lentiviral Vaccine Protection, Jodi K. Craigo, Corin Ezzelarab, Sheila J. Cook, Chong Liu, David W. Horohov, Charles J. Issel, Ronald C. Montelaro
Veterinary Science Faculty Publications
Lentiviral envelope (Env) antigenic variation and associated immune evasion present major obstacles to vaccine development. The concept that Env is a critical determinant for vaccine efficacy is well accepted, however defined correlates of protection associated with Env variation have yet to be determined. We reported an attenuated equine infectious anemia virus (EIAV) vaccine study that directly examined the effect of lentiviral Env sequence variation on vaccine efficacy. The study identified a significant, inverse, linear correlation between vaccine efficacy and increasing divergence of the challenge virus Env gp90 protein compared to the vaccine virus gp90. The report demonstrated approximately 100% protection …
Infectious Cdna Clone Of The Modified Live Virus Vaccine Strain Of Equine Arteritis Virus, Udeni B. R. Balasuriya, Peter J. Timoney, Jianquan Wang
Infectious Cdna Clone Of The Modified Live Virus Vaccine Strain Of Equine Arteritis Virus, Udeni B. R. Balasuriya, Peter J. Timoney, Jianquan Wang
Veterinary Science Faculty Patents
An isolated polynucleotide molecule includes a DNA sequence encoding an infectious RNA molecule encoding a modified live viral strain of an Equine arteritis virus, wherein the DNA sequence is SEQ ID NO:1 or a degenerate variant thereof. Also provided are transformed or transfected host cells including that sequence, vectors including the sequence, and isolated infectious RNA molecules encoded by the sequence. Further, a modified DNA sequence encoding an infectious RNA molecule encoding a modified live viral strain of an Equine arteritis virus is provided wherein the DNA sequence is SEQ ID NO:2 or a degenerate variant thereof, including a silent …
Inactivated Equine Rhinopneumonitis Virus Vaccine And Use Thereof, John T. Bryans
Inactivated Equine Rhinopneumonitis Virus Vaccine And Use Thereof, John T. Bryans
Veterinary Science Faculty Patents
An inactivated viral vaccine for protecting horses against disease caused by equine rhinopneumonitis virus is prepared by propagating an equine rhinopneumonitis virus in a susceptible, cloned, diploid equine cell line, harvesting the resulting virus in a serum-free medium, inactivating the virus and neutralizing the inactivating agent, concentrating the virus, and adding an immunological adjuvant thereto. A vaccination program to protect horses against the equine rhinopneumonitis virus is also disclosed.
Process Of Producing Equine Viral Arteritis Vaccine And Product Thereof, John T. Bryans, William H. Mccollum, James C. Wilson, Elvis R. Doll
Process Of Producing Equine Viral Arteritis Vaccine And Product Thereof, John T. Bryans, William H. Mccollum, James C. Wilson, Elvis R. Doll
Veterinary Science Faculty Patents
A process is disclosed for producing an avirulent attenuated live virus vaccine for use in immunizing horses against equine viral arteritis and for simultaneously obviating the transmission of the disease from a vaccinated horse to a non-vaccinated horse. The invention also includes the product derived from practice of the process and typical examples of the efficacy of the product are disclosed.